Jagsonpal Pharmaceuticals

Jagsonpal Pharmaceuticals

216.04
-0.62
(-0.29%)
hide
Key Fundamentals
Add Ratio
Market Cap
1,443.60 Cr
EPS
8.26
PE Ratio
23.29
Dividend Yield
1.15 %
Industry
Healthcare
52 Week High
328.04
52 Week Low
192.85
PB Ratio
5.70
Debt to Equity
0.04
Forecast For
Actual

Company News

View All News
Caret
neutral
Jagsonpal Pharmaceuticals Limited reported flat quarterly performance with revenue at Rs. 74.5 crores, impacted by GST transition challenges. The company maintained EBITDA at Rs. 18.1 crores with 24.3% margin and PAT grew 10% to Rs. 12.6 crores. For H1 FY26, revenue increased 10% to Rs. 150 crores with PAT jumping 39% to Rs. 23.4 crores. The company appointed Amrut Medhekar as Chief Operating Officer, bringing 30 years of pharma experience from Wockhardt, Zydus, Ranbaxy and Torrent. Nirav Vora joined as Chief Financial Officer with 18 years of finance experience. The Indian pharmaceutical market grew 7.5% in Q2 FY26, though Jagsonpal's therapy segments grew slower at 2.5-3%. GST reforms reduced rates from 12-18% to 5% but created temporary September challenges. The company paid dividends of Rs. 16.7 crores while maintaining cash position of Rs. 160.4 crores. Management expects stronger second-half performance and targets low double-digit growth for the remainder of the year.
neutral
Jagsonpal Pharmaceuticals Limited announced its unaudited financial results for the quarter and half year ended September 30, 2025. The Board of Directors approved these results at a meeting held on November 3, 2025. During the quarter, the company granted 272,500 stock options to eligible employees under its Employee Stock Option Plan 2022 and allotted 104,774 equity shares upon exercise of vested stock options. The company paid a final dividend of Rs. 2.5 per equity share (face value Rs. 2 each), totaling Rs. 166.58 million for the year ended March 31, 2025, following shareholder approval at the Annual General Meeting held on September 24, 2025. The company operates primarily in manufacturing and trading of pharmaceutical products including active pharmaceutical ingredients for customers in India and overseas. The results were reviewed by the Audit Committee and a limited review was conducted by statutory auditors Walker Chandiok & Co LLP.
neutral
Jagsonpal Pharma announced its Q2 financial results showing net profit increased to 126 million rupees from 115 million rupees year-over-year. However, revenue declined slightly to 745 million rupees from 747 million rupees in the same period last year. The company's EBITDA grew to 165 million rupees compared to 162 million rupees year-over-year, while EBITDA margin improved to 22.15% from 21.69% in the previous year's corresponding quarter.
View more
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
1,691.40
#1 4,04,503.90
38.74
#1 54,729.00
9.71
#1 10,980
2.89
55.98
6,656.50
1,82,735.30
71.11
9,712.00
18.67
2,191
35.10
58.39
1,505.70
1,21,284.30
22.36
28,409.50
7.12
5,291
3.71
40.84
3,580.00
1,21,163.50
60.51
11,539.40
6.99
1,911
30.46
50.54
1,205.40
1,00,587.70
#1 17.53
33,741.20
16.73
5,725
-0.38
37.06
2,261.80
95,310.10
52.66
12,744.20
#1 20.90
2,007
-21.05
25.15
944.10
94,253.90
18.88
23,511.00
18.55
4,615
34.60
33.87
1,971.80
89,318.30
20.71
22,909.50
13.74
3,306
#1 72.75
53.33
5,668.50
67,476.50
29.08
13,458.30
3.70
2,216
21.39
63.91
1,123.80
66,246.20
19.24
32,345.60
9.43
3,484
3.81
53.78
Growth Rate
Revenue Growth
27.02 %
Net Income Growth
146.22 %
Cash Flow Change
57.24 %
ROE
92.41 %
ROCE
81.03 %
EBITDA Margin (Avg.)
44.20 %

Yearly Financial Results

Annual Financials
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
Revenue
138
144
144
127
168
161
192
221
242
218
277
317
Expenses
129
132
138
138
158
150
169
193
203
186
218
228
EBITDA
9
13
6
-11
11
11
24
29
40
32
59
89
Operating Profit %
6 %
8 %
4 %
-9 %
6 %
5 %
10 %
12 %
14 %
11 %
19 %
19 %
Depreciation
3
3
2
0
1
1
1
2
1
2
8
9
Interest
5
5
3
1
1
1
1
0
0
1
1
1
Profit Before Tax
2
4
14
-12
9
9
22
27
35
30
70
79
Tax
1
1
3
-0
2
2
5
8
8
7
15
16
Net Profit
1
3
12
-12
7
8
17
19
27
23
55
62
EPS in ₹
0.45
1.24
4.53
-4.41
2.75
3.00
6.51
7.20
10.20
8.49
8.26
9.20

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total Assets
154
159
143
130
136
147
164
164
195
217
278
Fixed Assets
52
52
22
21
22
22
26
23
24
9
95
Current Assets
96
101
110
95
98
95
121
109
165
199
161
Capital Work in Progress
0
0
0
3
4
4
0
0
0
0
0
Investments
0
0
0
0
0
11
15
51
1
0
0
Other Assets
102
108
121
106
110
109
123
91
170
208
184
Total Liabilities
154
159
143
130
136
147
164
164
195
217
278
Current Liabilities
55
57
29
29
28
33
40
27
28
19
26
Non Current Liabilities
4
4
3
3
3
3
2
5
9
11
12
Total Equity
95
98
110
98
105
111
122
133
159
187
240
Reserve & Surplus
82
85
97
85
91
98
109
120
146
174
226
Share Capital
13
13
13
13
13
13
13
13
13
13
13

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Net Cash Flow
2
1
5
-6
24
-1
19
-36
-12
2
-2
Investing Activities
-1
-2
41
-3
-1
-11
-2
-26
-58
-25
-45
Operating Activities
4
9
-3
-2
31
11
28
7
47
35
55
Financing Activities
-1
-6
-34
-1
-6
-1
-7
-18
-1
-9
-12

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Promoter
70.34 %
70.34 %
70.34 %
70.34 %
68.71 %
68.71 %
68.71 %
68.71 %
68.71 %
68.71 %
68.71 %
68.48 %
68.09 %
68.04 %
67.97 %
67.81 %
67.78 %
67.65 %
67.54 %
FIIs
0.00 %
0.00 %
0.11 %
0.20 %
0.00 %
0.00 %
0.13 %
0.00 %
0.00 %
0.00 %
0.38 %
0.00 %
0.73 %
1.10 %
2.30 %
2.10 %
2.10 %
2.18 %
2.12 %
DIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.28 %
0.77 %
0.83 %
0.83 %
0.83 %
0.00 %
0.85 %
0.85 %
0.11 %
0.00 %
0.00 %
0.05 %
0.09 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
26.67 %
26.08 %
23.71 %
23.71 %
22.92 %
25.27 %
22.78 %
21.11 %
22.23 %
22.84 %
21.99 %
21.94 %
20.69 %
20.79 %
20.38 %
20.64 %
20.94 %
24.26 %
21.13 %
Others
2.98 %
3.57 %
5.83 %
5.75 %
8.36 %
6.02 %
8.10 %
9.40 %
8.23 %
7.62 %
8.09 %
9.58 %
9.64 %
9.22 %
9.24 %
9.45 %
9.17 %
5.86 %
9.12 %
No of Share Holders
0
12,546
14,655
14,353
20,031
17,100
16,194
14,952
14,084
13,782
16,041
15,785
16,282
15,748
15,633
18,471
21,085
22,899
24,653

Dividend History

Annual Cash Flows 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dividend Per Share (₹) 0.1 0.1 0.1 0.25 0.5 1 4 5 5 2.5
Dividend Yield (%) 0.66 0.93 0.95 3.56 1.57 0.8 3.45 4.52 2.3 1.15

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
24 Sept 2021 DIVIDEND Dividend
₹ 1.00 /share
22 Sept 2021 61.54 61.64
01 Nov 2021 DIVIDEND Dividend
₹ 4.00 /share
29 Oct 2021 64.98 69.88
17 Jun 2022 EXTRAORDINARY GENERAL MEETING Extraordinary General Meeting
NA
17 Jun 2022 118.24 111.40
21 Aug 2023 DIVIDEND Dividend
₹ 5.00 /share
21 Aug 2023 141.58 183.34
06 Sept 2024 DIVIDEND Dividend
₹ 5.00 /share
06 Sept 2024 144.42 167.08
18 Sept 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
18 Sept 2024 144.54 164.02
23 Oct 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
23 Oct 2024 181.68 183.76
23 Oct 2024 SPLIT Split
2:5
08 Jan 2025 183.76 183.76
22 Jan 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
22 Jan 2025 215.25 222.00
06 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
06 May 2025 232.50 250.05
26 Jul 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
26 Jul 2025 262.50 263.29
12 Sept 2025 DIVIDEND Dividend
₹ 2.50 /share
12 Sept 2025 250.05 247.82
24 Sept 2025 ANNUAL GENERAL MEETING Annual General Meeting
NA
24 Sept 2025 263.29 241.89
03 Nov 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
03 Nov 2025 216.10 222.84

Announcements

Announcement under Regulation 30 (LODR)-Earnings Call Transcript12 hours ago
Announcement under Regulation 30 (LODR)-Newspaper Publication2 days ago
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome3 days ago
Announcement under Regulation 30 (LODR)-Press Release / Media Release4 days ago
Announcement under Regulation 30 (LODR)-Investor Presentation4 days ago
Unaudited Financial Results For The Quarter And Half Year Ended September 30 20254 days ago
Board Meeting Outcome for Outcome Of Board Meeting4 days ago
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation9 days ago
Board Meeting Intimation for Intimation For Board Meeting.Oct 27, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 09, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSOct 07, 2025
Intimation Under Regulation 30 (5) Of The SEBI (LODR) Regulations 2015Oct 07, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementOct 07, 2025
Closure of Trading WindowSep 26, 2025
Shareholder Meeting / Postal Ballot-Scrutinizers ReportSep 26, 2025
Shareholder Meeting / Postal Ballot-Outcome of AGMSep 24, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationSep 20, 2025
Reg. 34 (1) Annual Report.Sep 19, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseSep 04, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementSep 04, 2025
Letter To Shareholders For Annual Report Web-Link And PathSep 02, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationSep 02, 2025
Business Responsibility and Sustainability Reporting (BRSR)Sep 01, 2025
Notice Of 46Th Annual General Meeting Of The CompanySep 01, 2025
Reg. 34 (1) Annual Report.Sep 01, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 13, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSAug 08, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptJul 31, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeJul 28, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 28, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 26, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationJul 26, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 26, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationJul 26, 2025
The 46Th Annual General Meeting Of The Company Will Be Held On September 24 2025 Dividend- Record Date Will Be September 12 2025 Jul 26, 2025
Results- Financial Results For The Quarter Ended June 30 2025Jul 26, 2025
Board Meeting Outcome for Outcome Of Board Meeting Along With Unaudited Financial Results For The Quarter Ended June 30 2025Jul 26, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSJul 24, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSJul 24, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJul 23, 2025
Board Meeting Intimation for Consideration And Approval Of Un- Audited Financial Results For The Quarter Ended June 30 2025Jul 23, 2025
Announcement under Regulation 30 (LODR)-CessationJul 08, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 07, 2025
Closure of Trading WindowJun 26, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 16, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSJun 11, 2025
Announcement under Regulation 30 (LODR)-Change in Registered Office AddressJun 02, 2025
Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 27, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptMay 13, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 08, 2025

Mutual Fund Holdings

Funding HouseCurrent Holding %1M Change1M Change %3M Change %Last 6M Trend
Bandhan BSE Healthcare Index Fund Direct-Growth
0.00%
-260
-0.03%
0.00%
WhiteOak Capital Pharma and Healthcare Fund Direct - Growth
0.00%
0
0.00%
0.00%

Technical Indicators

RSI(14)
Neutral
43.88
ATR(14)
Less Volatile
7.16
STOCH(9,6)
Neutral
49.73
STOCH RSI(14)
Neutral
46.25
MACD(12,26)
Bullish
0.83
ADX(14)
Weak Trend
18.55
UO(9)
Bearish
42.51
ROC(12)
Downtrend And Accelerating
-1.32
WillR(14)
Oversold
-83.38